Home > Healthcare > Pharmaceuticals > Finished Drug Form > Vulvovaginal Candidiasis (VVC) Treatment Market

Vulvovaginal Candidiasis (VVC) Treatment Market Share

Report ID: GMI9746
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Vulvovaginal Candidiasis Treatment Market Share

The competitive landscape of the vulvovaginal candidiasis (VVC) treatment market is characterized by the presence of several key players, including pharmaceutical companies, and biotechnology companies. These entities compete to develop and commercialize VVC treatments, aiming to capture market share and meet the evolving needs of patients.

Vulvovaginal Candidiasis Treatment Market Companies

Prominent players operating in the vulvovaginal candidiasis treatment industry include:

Accord Healthcare Ltd.
Amneal Pharmaceuticals LLC
Astellas Pharma Inc.
Basilea Pharmaceutica Ltd.
Bayer AG
Bristol-Myers Squibb Company
Grupo Ferrer Internacional S.A.
Johnson & Johnson
Mycovia Pharmaceuticals, Inc.
Mylan N.V.
Pfizer, Inc.
Scynexis, Inc.
Teva Pharmaceutical Industries Ltd.
Zydus Cadila

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The vulvovaginal candidiasis treatment market was valued at USD 1 billion in 2023 and is poised to grow at 4.5% CAGR during 2024-2032, attributed to the increasing prevalence of VVC worldwide.

The uncomplicated segment held 60.2% of the vulvovaginal candidiasis (VVC) treatment market share in 2023 and will grow rapidly through 2032, owing to its high prevalence.

North America vulvovaginal candidiasis treatment market was valued at USD 418.2 million in 2023 and is expected to reach USD 613.7 million by 2032, owing to the presence of a well-developed healthcare system with state-of-the-art medical facilities.

Accord Healthcare Ltd, Amneal Pharmaceuticals LLC, Astellas Pharma Inc, Basilea Pharmaceutica Ltd, Bayer AG, Bristol-Myers Squibb Company, Grupo Ferrer Internacional S.A, Johnson & Johnson, and Mycovia Pharmaceuticals, Inc. among others.